Accolate - Well tolerated in long-term treatment

FAQ

International website for respiratory experts

Accolate is well tolerated and the overall safety profile has also been confirmed in over 1.4 million patients receiving Accolate in the clinical setting (AstraZeneca data on file 16).

References
Data on file 16 – AstraZeneca

back to top

Highly potent and selective cysteinyl leukotriene receptor antagonist

Blocks the effects of leukotriene-related inflammatory response in airways

Effective control of asthma, either in combination with other controller therapies or as an alternative to first-line use of low-dose inhaled glucocorticosteroids

Complementary mechanism of action to inhaled corticosteroids

Provides the confidence of day and night control of asthma

Unsurpassed compliance from twice-daily tablet therapy

Well tolerated in long-term treatment

Different formulations of Accolate

Alternative names for Accolate

Bibliography

Prescribing
information

Images